ReviewNature reviews. Gastroenterology & hepatology2026
Liver disease in people living with HIV infection: a changing landscape.
Review in Nature reviews. Gastroenterology & hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A people-first, systems-oriented approach to liver disease in HIV infection.Nature reviews. Gastroenterology & hepatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As persons living with human immunodeficiency virus (HIV) infection are living longer, non-AIDS-related mortality continues to rise, with liver disease being one of the most common causes. This Review provides a synopsis of the current burden of liver diseases, ranging from viral hepatitis to metabolic dysfunction-associated steatotic liver disease to liver cancer, and discusses the barriers and challenges to screening and treatment as well as cofactors contributing to increasing disease burden. A brief insight is provided on the potential molecular mechanisms driving hepatic inflammation and fibrosis in persons living with HIV. Given the effect of direct-acting antivirals on hepatitis C virus infection and suppressive treatment for hepatitis B virus infection, special attention is drawn to the emergence of metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis in this population, focusing on factors related to the increasing prevalence of relevant comorbidities, the role of antiretroviral therapy, and HIV-specific factors in driving liver fibrosis progression.
Indexed as
Identifiers
41286031What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.